Actively Recruiting
Phase 3 Randomized Study Comparing Oral NX-5948 and Pirtobrutinib in Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Led by Nurix Therapeutics, Inc. · Updated on 2026-08-31
620
Participants Needed
6
Research Sites
200 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of two oral drugs, NX-5948 and pirtobrutinib, in adults with relapsed or refractory chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. Participants must have previously received treatment with a covalent Bruton tyrosine kinase inhibitor cBTKi but experienced disease progression. This Phase 3, randomized, open-label study compares these treatments to better understand their impact on disease control. Participants are randomly assigned to receive either NX-5948 or pirtobrutinib, both taken orally once daily. The study treatment continues with regular monitoring, and the research team assesses outcomes such as progression-free survival and objective response rates over several years. The trial also evaluates overall survival, duration of response, quality of life measures, and safety through lab tests and adverse event tracking. During the trial, participants will have scheduled visits for assessments including imaging scans, laboratory tests, and questionnaires about health status and quality of life. Researchers will monitor vital signs and collect pharmacokinetic data for NX-5948. The study may last up to approximately seven years, with ongoing evaluations to understand the long-term effects and safety of the study drugs in this patient population.
CONDITIONS
Brief Title
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
Research Team
A
Additional Site Contact Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here